Applying the Rome Proposal on Exacerbations of Chronic Obstructive Pulmonary Disease: Does Comorbid Chronic Heart Failure Matter?

References

• Torén K, Schiöler L, Lindberg A, et al. Chronic airflow limitation and its relation to respiratory symptoms among ever-smokers and never-smokers: a cross-sectional study. BMJ Open Respir Res. 2020;7(1):e000600. doi:10.1136/bmjresp-2020-000600
   PubMed Web of Science ®Google Scholar
• Kentson M, Leanderson P, Jacobson P, Persson HL. The influence of disease severity and lifestyle factors on the peak annual 25(OH)D value of COPD patients. Int J Chron Obstruct Pulmon Dis. 2018;13:1389–1398. doi:10.2147/COPD.S156121
   PubMed Web of Science ®Google Scholar
• Malinovschi A, Zhou X, Bake B, et al. Assessment of Global Lung Function Initiative (GLI) reference equations for diffusing capacity in relation to respiratory burden in the Swedish CArdioPulmonary bioImage Study (SCAPIS). Eur Respir J. 2020;56(2):1901995. doi:10.1183/13993003.01995-2019
   PubMed Web of Science ®Google Scholar
• Persson HL, Sioutas A, Jacobson P, Vainikka LK. Human lung macrophages challenged to oxidants ex vivo: lysosomal membrane sensitization is associated with inflammation and chronic airflow limitation. J Inflamm Res. 2020;13:925–932. doi:10.2147/JIR.S280419
   PubMed Web of Science ®Google Scholar
• Sioutas A, Vainikka LK, Kentson M, et al. Oxidant-induced autophagy and ferritin degradation contribute to epithelial-mesenchymal transition through lysosomal iron. J Inflamm Res. 2017;10:29–39. doi:10.2147/JIR.S128292
   PubMed Web of Science ®Google Scholar
• Persson HL, Richardson DR. Iron-binding drugs targeted to the lysosomes: a potential strategy to treat inflammatory lung disorders. Expert Opin Investig Drugs. 2005;14(8):997–1008. doi:10.1517/13543784.14.8.997
   PubMed Web of Science ®Google Scholar
• Kentson M, Leanderson P, Jacobson P, Persson HL. Oxidant status, iron homeostasis, and carotenoid levels of COPD patients with advanced disease and LTOT. Eur Clin Respir J. 2018;5(1):1447221. doi:10.1080/20018525.2018.1447221
   PubMedGoogle Scholar
• Persson HL, Sioutas A, Kentson M, et al. Skeletal myosteatosis is associated with systemic inflammation and a loss of muscle bioenergetics in stable COPD. J Inflamm Res. 2022;15:4367–4384. doi:10.2147/JIR.S366204
   PubMed Web of Science ®Google Scholar
• Ekström MP, Blomberg A, Bergström G, et al. The association of body mass index, weight gain and central obesity with activity-related breathlessness: the Swedish Cardiopulmonary Bioimage Study. Thorax. 2019;74(10):958–964. doi:10.1136/thoraxjnl-2019-213349
   PubMed Web of Science ®Google Scholar
• Van Eeden S, Leipsic J, Paul Man SF, Sin DD. The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med. 2012;186(1):11–16. doi:10.1164/rccm.201203-0455PP
   PubMed Web of Science ®Google Scholar
• Ellingsen J, Johansson G, Larsson K, et al. Impact of comorbidities and commonly used drugs on mortality in COPD - real-world data from a primary care setting. Int J Chron Obstruct Pulmon Dis. 2020;15:235–245. doi:10.2147/COPD.S231296
   PubMed Web of Science ®Google Scholar
• Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–639. doi:10.1016/s2213-2600(15)00241-6
   PubMed Web of Science ®Google Scholar
• Horodinschi R-N, Bratu OG, Dediu GN, Pantea Stoian A, Motofei I, Diaconu CC. Heart failure and chronic obstructive pulmonary disease: a review. Acta Cardiol. 2020;75(2):97–104. doi:10.1080/00015385.2018.1559485
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2023 report. [homepage on the Internet]; 2023. Available from: https://goldcopd.org/2023-gold-report-2/. Accessed March 8, 2023.
   Google Scholar
• Celli B, Fabbri LM, Aaron SD, et al. An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the Rome proposal. ATS J. 2021;204(11):1251–1258. doi:10.1164/rccm.202108-1819PP
   Google Scholar
• Althobiani MA, Shah AJ, Khan B, Hurst JR. Clinicans’ and researchers’ perspectives on a new chronic obstructive pulmonary disease exacerbation definition: Rome Wasn’t Built in a day. Am J Respir Crit Care Med. 2023;207(8):1095–1097. doi:10.1164/rccm.202210-1949LE
   PubMed Web of Science ®Google Scholar
• Persson HL, Lyth J, Wiréhn A-B, Lind L. Elderly patients with COPD require more health care than elderly heart failure patients do in a hospital-based home care setting. Int J Chron Obstruct Pulmon Dis. 2019;14:1569–1581. doi:10.2147/COPD.S207621
   PubMed Web of Science ®Google Scholar
• Persson HL, Lyth J, Lind L. The health diary telemonitoring and hospital-based home care improve quality of life among elderly multimorbid COPD and Chronic heart failure subjects. Int J Chron Obstruct Pulmon Dis. 2020;15:527–541. doi:10.2147/COPD.S236192
   PubMed Web of Science ®Google Scholar
• Lyth J, Lind L, Persson HL, Wiréhn A-B. Can a telemonitoring system lead to decreased hospitalization in elderly patients? J Telemed Telecare. 2021;27(1):46–53. doi:10.1177/1357633X19858178
   PubMed Web of Science ®Google Scholar
• Jacobson PK, Lind L, Persson HL. Unleashing the power of very small data to predict acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2023;18:1457–1473. doi:10.2147/COPD.S412692
   PubMed Web of Science ®Google Scholar
• Jacobson PK, Lind L, Persson HL. The exacerbation of chronic obstructive pulmonary disease: which symptom is most important to monitor? Int J Chron Obstruct Pulmon Dis. 2023;18:1533–1541. doi:10.2147/COPD.S417735
   PubMedGoogle Scholar
• A healthy lifestyle. [homepage on the internet]. Available from: https://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi. Accessed March 15, 2023.
   Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Hedenström H, Malmberg P, Agarwal K. Reference values for lung function tests in females. regression equations with smoking variables. Bull Eur Physiopathol Respir. 1985;21(6):551–557.
   PubMedGoogle Scholar
• Hedenström H, Malmberg P, Fridriksson H. Reference values for lung function tests in men: regression equations with smoking variables. Ups J Med Sci. 1986;91(3):299–310. doi:10.3109/03009738609178670
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines or the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975. doi:10.1002/ejhf.592
   PubMed Web of Science ®Google Scholar
• Giezeman M, Sundh J, Athlin Å, et al. Comorbid heart disease in patients with COPD is associated with increased hospitalization and mortality – a 15-year follow-up. Int J Chron Obstruc Pulmon Dis. 2023;18:11–21. doi:10.2147/COPD.S378979
   PubMed Web of Science ®Google Scholar
• Reumkens C, Endres A, Simons SO, Savelkoul PHM, Sprooten RTM, Franssen FME. Application of the Rome severity classification of COPD exacerbations in a real-world cohort of hospitalized patients. Eur Respir Soc. 2023;9(2). doi:10.1183/23120541.00569-2022
   Google Scholar
• Giezeman M, Hasselgren M, Lisspers K, et al. Influence of comorbid heart disease on dyspnea and health status in patients with COPD – a cohort study. Int J Chron Obstruct Pulmon Dis. 2018;13:3857–3865. doi:10.2147/COPD.S175641
   PubMed Web of Science ®Google Scholar